Financials
Financial year 2025
HCL PHARMA from Walcourt, company number BE0649663933, closed financial year 2025 with a result of € 36,408 after tax. For that financial year HCL PHARMA recorded a gross margin of € 82,841 and equity of € 57,108. Compared with financial year 2024, the result moved from € 5,934 to € 36,408. Profitable, and profit is growing. The buffer shrank hard: equity is 53 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ 57,108
▼ 53% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 36,408
▲ € 30,474 vs 2024
Profit after tax over the fiscal year.
€ 44,170
▲ 244% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 106,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 9,111
▲ 85% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 237,787
▼ 11% vs 2024
€ 28,839 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 3,619
▲ 29% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 19,735
▲ 256% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 36,888 | € 51,551 | € 43,973 | € 82,841 | ▲ 88% |
| Profit after taxes | € 3,766 | € 13,340 | € 5,934 | € 36,408 | ▲ € 30,474 |
| Equity | € 101,226 | € 114,566 | € 120,500 | € 57,108 | ▼ 53% |
| Total debts | € 402,153 | € 385,699 | € 365,575 | € 445,107 | ▲ 22% |
| Cash | € 5,748 | € 20,429 | € 12,852 | € 44,170 | ▲ 244% |
| Land & buildings | € 317,881 | € 309,798 | € 286,255 | € 267,987 | ▼ 6% |
| Retained profit | € 88,826 | € 102,166 | € 108,100 | € 38,508 | ▼ 64% |
| Dividend | € 0 | € 0 | € 0 | € 106,000 | |
| Bank debt | € 321,946 | € 294,276 | € 266,232 | € 237,787 | ▼ 11% |
| Balance sheet total | € 503,379 | € 500,265 | € 486,075 | € 502,215 | ▲ 3% |
Key figures of HCL PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to HCL PHARMA?
What happened at HCL PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 36,408 (▲ € 30,474 vs 2024). Source: NBB ↗
- New establishment in Walcourt. KBO
- New establishment in Walcourt. KBO
- Start of the company according to the CBE. KBO
- Hélène De Groote became a director. NBB
In short
From € 3,766 profit in 2022 to € 36,408 profit in 2025.
Paid € 19,084 in corporate taxes since 2022.
Best year ever: 2025, with € 36,408 profit.
Paid out € 106,000 in dividends to the owners in total.
Management
Behind HCL PHARMA is Hélène De Groote. It owns 96% of Pharmacie De Groote itself.
Directors
According to the 2025 annual accounts
Hélène De Groote
Director
since 2016
Establishments
Establishment units
Physical locations of this company
Rue du Jardinet(Wal) 6 box 2
5650 Walcourt
Grand'Place(Wal) 37
5650 Walcourt
Active since 6 March 2016
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0649.663.933
- VAT number
- BE 0649.663.933
- Registered office
- Rue du Jardinet(Wal) 6 bus 2, 5650 Walcourt
- Names & denominations
- HCL PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 6 March 2016
- Peppol
- Active · Active since 20 Nov 2020
- Contact
- [email protected] 071611476
- Activities · NACE
Detailhandel in farmaceutische producten